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BACKGROUND AND OBJECTIVE 
Diabetes is one of the most common co-morbid illness in our 
community. 
One of its complication in long course is diabetic foot. 
Morbidity and mortality due to this complication is a major health 
issue. This study is aimed to evaluate and manage the different 
lesions of diabetic foot according to Wagner classification.  
To describe the lesions we treat study and compare outcomes 
and to identify measures to decrease morbidity and mortality due  to 
diabetic foot disease 
METHODS 
Between July 2015 and September 2015, 50 patients with 
diabetic foot who got admitted to Institute of General Surgery,Rajiv 
Gandhi Government General Hospital,Chennaiwere subjected to 
surgical treatment depending upon the Wagner’s classification. 
Data was collected and analyzed. 
RESULTS 
Majority of the patients presented with higher grade and with 
poor glycemic control at the time of presentation. Conservative 
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management with antibiotics was useful in a small subset of the 
patients. Majority of the patients needed surgical treatment in the 
form of debridement to amputations.   
INTERPRETATION AND CONCLUSION 
Patient education and strict glycemic control can reduce the 
burden of diabetic foot. Early diagnosis and hospitalization, 
appropriate treatment including medical and surgical treatment 
according to the grade can reduce the morbidity mortality and 
improve the outcome of the disease.  
KEY WORDS: Antibiotics; Amputation; Wagner 
classification; Complications; Glycemic control 
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 “WAGNER’S CLASSIFICATION FOR DIABETIC 
FOOT DISEASE (ADOPTED FROM LEVIN  
AND O’NEALS)” 
Grade Description 
Grade 0 High risk foot and no ulceration 
Grade 1 Superficial Ulcer; Total 
destruction of the thickness of the 
skin  
Grade 2 Deep Ulcer (cellulitis); Penetrates 
through skin,fat,ligaments not 
affecting bone 
Grade 3 Osteomyelitis with Ulceration or 
abscess 
Grade 4 Gangrenous patches limited to 
toes or part of the foot 
Grade 5 Gangrene of the entire foot  
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Four categories of diabetes are recognized . Type 1, formerly 
insulin-dependent diabetes mellitus (IDDM), is an autoimmune 
disease affecting the pancreas. Individuals with type 1 diabetes are 
prone to ketosis and unable to pro duce endogenous insulin. Type 2, 
formerly non-insulin dependent diabetes mellitus (NIDDM), 
accounts for 90% to 95% of cases diagnosed. Type 2 diabetes is 
characterized by hyperglycemia in the presence of hyperinsulinemia 
due to peripheral insulin resistance. Gestational as well as  genetic 
defects and endocrinopathies are recognized as other types of 
diabetes (11). Diabetes is associated with numerous complications 
related to microvascular, macrovascular, and metabolic etiologies. 
These include cerebrovascular, cardio- vascular, and peripheral 
arterial disease; retinopathy; neuropathy; and nephropathy. 
Currently, cardiovascular complications are the most common 
cause of premature death. Diabetes continues to de  one  o f  the 
most common underlying cause of non-traumatic lower extremity 
amputations (LEAs) 
EPIDEMIOLOGY  4A 
 ―Mean age at diagnosis of diabetic foot and mean  age at 
major amputation was significantly lower as compared to Western 
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literature. This should be the sole reason to explain favourable 
results seen in Indian series specially in reference to survival at 2 
years after major amputation, contralateral limb amputation rate, 
above knee to below knee amputation rate. Older patients reported 
in Western literature are more likely to have advanced 
atherosclerotic disease involving heart, cerebral circulation, 
peripheral circulation and renal circulation thus adversely affecting 
mortality and contralateral limb amputation rate. Above knee 
amputation was common in Western population and above knee to 
below knee amputation ratio was 1:2 vs. 1:17 in Western vs. Indian 
series.‖ 
 ―Majority of  Indian patients have infection as  a dominant 
feature in non-neuroischemic foot. In such cases local debridement, 
control of infection and diabetes, certainly improves the limb 
salvage. If the infection is fulminant, minor or at the most below 
knee amputation is enough to stop the advancing infective process. 
As against this in Western patients, where old age and 
neuroischemic limbs are common, advanced atherosclerosis, and 
multi- system involvement makes above knee amputation perhaps 
the right choice to reduce the overall mortality.‖ 
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 ―In one population-based study in Sweden (1) the cost of 
treating foot ulcer was US$ 14,627 as compared to US$ 500 in our  
patients. The  cost    of treatment in-patients undergoing amputation 
was US$ 73,702 in Sweden as compared to US$ 2000 in our 
patients. This difference in cost of treatment is obviously due to 
marked economic disparity in two populations. Although cost of 
private treatment in India is less, majority of our patients have to  
bear the entire cost of the treatment as they are not medically 
insured and for them even this cost is substantial.‖ 
―Although present study shows favourable results  in Indian 
patients as compared to Western, it will not be surprising if one 
sees the change in scenario in next ten to thirty years. In India the 
number of amputation in diabetic patients is bound to increase due 
to several factors like increasing prevalence of diabetes, longer 
survival, more ageing population, continued use of tobacco, 
barefoot walking, careless home surgical attempt, late reporting to 
medical centre and poor hygienic conditions. Unless urgent steps 
are taken, India might emerge as  a country with highest rate of 
amputations for diabetic foot.‖ 
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OBJECTIVES 
The purpose of this dissertation is to evaluate and manage 
diabetic foot according to Wagner’s classification at Institute of 
General surgery, Rajiv Gandhi Government General Hospital, 
Chennai. 
The study period is between July 2015 to September  2015. 
1) To evaluate and manage the different lesions of diabetic foot 
according to Wagner classification. 
2) To describe the lesions we treat study and compare outcomes. 
3) To identify measures to decrease morbidity and mortality due 
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REVIEW OF LITERATURE 
―Diabetic foot ulcers occur as a result of various factors, 
such as mechanical changes in conformation of the bony 
architecture of the foot, peripheral neuropathy, and 
atherosclerotic peripheral arterial disease, all of which occur 
with higher frequency and intensity in the diabetic population.‖  
RISK FOR ULCERATION 
―Foot ulceration is the most common single precursor  to 
lower extremity amputations among persons with diabetes (28-30). 
Treatment of infected foot wounds comprises up to one quarter of 
all diabetic hospital admissions , making this the most common 
reason for diabetes- related hospitalization in these countries (41-
43). The multifactorial nature of diabetic foot ulceration has been 
elucidated by numerous observational studies (16, 22, 24, 26, 27, 44-
48). Risk factors identified include peripheral neuropathy, vascular 
disease, limited joint mobility, foot deformi- ties, abnormal foot 
pressures, minor trauma, a history of ulceration or amputation, and 
impaired visual acuity (25, 49, 50). These and other putative 
causative factors are shown in Figure 1.” 
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Figure 1 The risk factors for ulceration may be 
distinguished by general or systemic considerations versus those 
localized to the foot and its pathology. 
 
―Peripheral sensory neuropathy in the face of unperceived 
trauma is the primary factor leading to diabetic foot ulcerations (24, 
27, 46, 49). Approximately 45% to 60% of all diabetic ulcerations 
are purely neuropathic, while up to 45% have neuropathic and 
ischemic components (24, 51). According to an important 
prospective multicenter study, sensory neuropathy was the most 
frequent component in the causal sequence to ulceration in diabetic 
patients (24).‖ 
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 ―Other forms of neuropathy may also play a role in foot 
ulceration. Motor neuropathy resulting in anterior crural muscle 
atrophy or intrinsic muscle wasting can lead to foot deformities 
such as foot drop, equinus, hammertoe, and prominent plantar 
metatarsal heads (25, 26, 52-54). Ankle equinus with restricted 
dorsiflexory range of motion is fairly common in patients with 
diabetic neuropathy and can be a consequence of anterior crural 
muscle atrophy (55-60). The decreased ankle motion, which 
confers higher-than- normal plantar pressures at the forefoot, has 
been implicated as a contributory cause of ulceration as well as 
recurrence or recalcitrance of existing ulcers (57, 58, 60, 61).‖ 
 ―Autonomic neuropathy often results in dry skin  with 
cracking and fissuring, creating a portal of entry for  bacteria (42, 
63). Auto-sympathectomy with attendant sympathetic failure, 
arteriovenous shunting, and microvascular thermoregulatory 
dysfunction impairs normal tissue perfusion and microvascular 
responses to injury. These alterations can subsequently be 
implicated in the pathogenesis of ulceration (63-67).‖ 
―Foot deformities resulting from neuropathy,  abnormal 
biomechanics, congenital disorders, or prior surgical  inter- vention 
may result in high focal foot pressures and increased risk of 
 19 
ulceration (24, 48, 50, 57, 68-71). The effects of motor neuropathy 
occur relatively early and lead to foot muscle atrophy with 
consequent development of hammertoes, fat pad displacement, and 
associated increases in plantar forefoot pressures (53, 72-75). 
Although most deformities cause high plantar pressures and 
plantar foot ulcerations, medial and dorsal ulcerations may develop 
as a result of footwear irritation. Common deformities  might 
include prior partial foot amputations, prominent metatarsal heads, 
hammertoes, Charcot arthropathy, or hallux valgus (69, 76-79). A 
large prospective population-based study found that elevated 
plantar foot pressures are significantly associated with neuropathic 
ulceration and amputation (80). The study also revealed a trend for 
increased foot pressures as the number of pedal deformities 
increased.‖ 
Trauma to the foot in the presence of sensory neuropathy is 
an important component cause of ulceration (24).  While trauma 
may include puncture wounds and blunt injury, a common injury 
leading to ulceration is moderate repetitive stress associated with 
walking or day-to-day activity (69, 76, 81).  This is often 
manifested by callus formation under the metatarsal heads (48, 82, 
83). A recent report suggests that even with moderate activity, 
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ulceration may be precipitated by a higher degree of variability in 
activity or period- ic ―bursts‖ of activity (84). Shoe-related trauma 
has also been identified as a frequent precursor to foot ulceration 
(28, 51, 54, 85, 86). 
 ―Peripheral arterial disease (PAD) rarely leads to foot 
ulcerations directly. However, once ulceration develops, arterial 
insufficiency will result in prolonged healing, imparting an elevated 
risk of amputation (28, 87, 88). Additionally, attempts to resolve 
any infection will be impaired due to lack of oxygenation and 
difficulty in delivering antibiotics to the infection site. Therefore, 
early recognition and aggressive treatment of lower extremity 
ischemia are vital to lower limb salvage (30, 52, 89-91).‖ 
―Limited joint mobility has also been described as a potential 
risk factor for ulceration (92-94). Glycosylation of collagen as a 
result of longstanding diabetes may lead to stiffening of capsular 
structures and ligaments (cheiroarthropa- thy) (95). The subsequent 
reduction in ankle, subtalar, and first metatarsophalangeal (MTP) 
joint mobility has been shown to result in high focal plantar 
pressures with increased ulceration risk in patients with neuropathy 
(92, 96, 97). Several reports also attribute glycosylation and altered 
 21 
arrangement of Achilles tendon collagen to the propensity for 
diabetic patients to develop ankle equinus (98, 99).‖ 
Other factors frequently associated with heightened ulceration 
risk include nephropathy, poor diabetes control, duration of 
diabetes, visual loss, and advanced age (48,  69, 93, 100). 
 
Figure 2     Diabetes mellitus is responsible for a variety of 
foot pathologies contributing to the complications of ulceration and 
amputation. Multiple pathologies may be implicated, from vascular 
disease to neuropathy to mechanical trauma. 
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Soft tissue changes (other than cheiro arthropathy) in the feet 
of diabetic patients might also contribute to ulceration through the 
pathway of altered pressure distributions through the sole of the 
foot. Such alterations include a reported increased thickness of the 
plantar fascia with associated limitation of hallux dorsiflexion, 
decreased thickness of plantar soft tissue, accentuated 
hardness/stiffness of the skin, and a propensity to develop calluses 
(82, 96, 101-105). While these changes are presumably caused by 
glycosylation of collagen, their sum effect is to enhance plantar 
pressures in gait. In the presence of neuropathy, the accentuated 
plantar pressures can be implicated in the development of 
ulceration (70, 80, 92, 106). 
MECHANISMS OF INJURY 
―The multifactorial etiology of diabetic foot ulcers is 
evidenced by the numerous pathophysiologic pathways  that can 
potentially lead to this disorder (24, 43, 54, 62, 90, 107). Among 
these are two common mechanisms by which foot deformity and 
neuropathy may induce skin breakdown in persons with diabetes 
(69, 108, 109). 
The first mechanism of injury refers to prolonged low 
pressure over a bony prominence (ie, bunion or hammertoe 
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deformity). This generally ca uses wounds over the medial, lateral, 
and dorsal aspects of the forefoot and is associated with tight or ill-
fitting shoes. Shoe trauma, in concert with loss of protective 
sensation and concomitant foot deformity, is the leading event 
precipitating foot ulceration in persons with diabetes (24, 28, 57, 
85).‖ 
Regions of high pedal pressure are frequently associated with 
foot deformity (68, 73, 76, 77, 106, 107). When an abnormal 
focus of pressure is coupled with lack of protective sensation, the 
result can be development of a callus, blister, and ulcer (110).   
The  other  common mechanism of ulceration involves prolonged 
repetitive moderate stress (108). This normally occurs on the sole 
of the foot and is related to prominent metatarsal heads, atrophied or 
anterior- ly displaced fat pads, structural deformity of the lower 
extremity, and prolonged walking. Rigid deformities such as hallux 
valgus, hallux rigidus, hammertoe, Charcot arthropathy, and limited 
range of motion of the ankle (equi- nus), subtalar, and MTP joints 
have been linked to the development of diabetic foot ulcers (27, 57, 
71, 80, 94, 96). Numerous studies support the significant association 
between high plantar pressures and foot ulceration (26,  70, 80, 92, 
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106, 111, 112). Other biomechanical perturbations, including partial 
foot amputations, have the same adverse effects (57, 68, 80, 113). 
Figure 2 summarizes the various pathways and contribut- ing 
factors leading to diabetic foot complications. 
RISK FOR INFECTION 
―Infections are common in diabetic patients and are  often 
more severe than infections found in nondiabetic patients. Persons 
with diabetes have an increased risk for developing an infection of 
any kind and a several-fold risk for develop- ing osteomyelitis 
(114). With an incidence of 36.5 per 1,000 persons per year, foot 
infections are among the most com- mon lower extremity 
complications in the diabetic population (excluding neuropathy), 
second only to foot ulcers in frequency (115).‖ 
―It is well documented that diabetic foot infections are  
frequently polymicrobial in nature (30, 116-121). Hyperglycemia, 
impaired immunologic responses, neuropathy, and peripheral arterial 
disease are the major predisposing factors leading to limb-
threatening diabetic foot infections (122-124). Uncontrolled 
diabetes results in impaired ability of host leukocytes to fight 
bacterial pathogens, and ischemia also affects the ability to fight 
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infections because delivery of antibiotics to the site of infection is 
impaired. Consequently, infection can develop, spread rapidly,  and 
produce significant and irreversible tissue damage (125). Even in 
the presence of adequate arterial perfusion, under- lying peripheral 
sensory neuropathy will often allow the progression of infection 
through continued walking or delay in recognition (126, 127).‖ 
RISK FOR CHARCOT JOINT DISEASE 
 ―It has been estimated that less than 1% of persons with 
diabetes will develop Charcot joint disease (128-130). Data on the 
true incidence of neuroarthropathy in diabetes are limited by the 
paucity of prospective or population-based studies in the literature. 
One large population-based prospective study found an incidence of 
about 8.5 per 1,000 persons with diabetes per year (115); this 
equates to 0.85% per year and is probably the most reliable figure 
currently available. Much of the data clinicians rely upon have 
been extracted from retrospective studies of small, single-center 
cohorts. The incidence of reported Charcot cases is likely to be 
underestimated because many cases go undetected, espe- cially in 
the early stages (131-134).‖ 
 ―Primary risk factors for this potentially limb-threatening 
deformity are the presence of dense peripheral sensory neu- 
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ropathy, normal circulation, and history of preceding trau- ma 
(often minor in nature) (50, 135, 136). Trauma is not limited to 
injuries such as sprains or contusions. Foot deformities, prior 
amputations, joint infections, or surgical trauma may result in 
sufficient stress that can lead to Charcot joint disease (137-140).‖ 
RISK FOR AMPUTATION 
―The reported risk of lower extremity amputations in  dia- 
betic patients ranges from 2% to 16%, depending on study design 
and the populations studied (19, 21, 32, 115, 141- 144). LEA rates 
can be 15 to 40 times higher among the diabetic versus nondiabetic 
populations (8, 16, 34, 35). Although one author suggests that 
amputation may be a marker not only for disease severity but also 
for disease management, it is clear that amputation remains a 
global problem for all persons with diabetes (32, 143). The same 
risk factors that predispose to ulceration can also generally be 
considered contributing causes of amputation, albeit with several 
modifications (Fig 3).‖ 
―While peripheral arterial disease may not always be an 
independent risk factor for ulceration when controlling for 
neuropathy, it can be a significant risk factor for amputation (24, 28, 
88, 142, 145, 146). PAD affecting the feet and legs is present in 8% 
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of adult diabetic patients at diagnosis and in 45 % after 20 years 
(147, 148). The incidence of ampu- tation is 4 to 7 times greater 
for diabetic men and women than for their nondiabetic 
counterparts. Impairment of arte- rial perfusion may be an isolated 
cause for amputation and a predisposing factor for gangrene. Early 
diagnosis, control of risk factors, and medical management as well 
as timely revascularization may aid in avoiding limb loss (30, 52, 
77, 88, 149).‖ 
Figure 3 The risk factors for amputation are multifactorial 




―While infection is not often implicated in the pathway 
leading to ulceration, it is a significant risk factor in the causal 
pathway to amputation (24, 28). Lack of wound heal- ing, systemic 
sepsis, or unresolved infection can lead to extensive tissue 
necrosis and gangrene, requiring amputa- tion to prevent more 
proximal limb loss. This includes soft tissue infection with severe 
tissue destruction, deep space abscess, or osteomyelitis. Adequate 
debridement may require amputation at some level as a means of 
removing all infected material (77, 123, 150, 151).‖ 
―Another frequently described risk factor for amputation is 
chronic hyperglycemia. Results of the  Diabetes Control and 
Complications Trial (DCCT) and the United Kingdom Prospective 
Diabetes Study (UKPDS) support the long-held theory that chronic 
poor control of diabetes is associated with a host of systemic 
complications (152, 153). The link between degree of glucose 
control and incidence or pro- gression of numerous diabetic 
complications has been well established by these and other studies 
(154, 155). Such complications include peripheral neuropathy, 
microan- giopathy, microcirculatory disturbances, impaired leuko- 
cyte phagocytosis, and glycosylation of tissue proteins. Each has 
adverse effects on the diabetic foot: They can con- tribute to the 
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etiology of foot ulceration, delay normal wound healing, and 
subsequently lead to amputation (25, 30, 48, 50, 72). Several 
studies have reported a significant correlation  between  elevated  
glucose  and  LEA (21, 141,‖156-161). Amputation has also been 
associated with other diabetes-related comorbidities such as 
nephropathy, retinopathy, and cardiovascular disease (21, 48, 144). 
Aggressive glucose control, management of associated 
comorbidities, and appropriate lower extremity care coordi- nated 
in a team environment may indeed lower overall risk for amputation 
(30, 90, 162-166). 
―The best predictor of amputation is a history of previous 
amputation. A past history of a lower extremity ulceration or 
amputation increases the risk for further ulceration, infection, and 
subsequent amputation (29, 142, 157, 167). It may also be inferred 
that patients with previous ulceration possess all the risk factors for 
developing another ulcera- tion, having demonstrated that they 
already have the com- ponent elements in the causal pathway (24, 
27, 28, 57). Up to 34% of patients develop another ulcer within 1 
year after healing an index wound, and the 5-year rate of 
developing a new ulcer is 70% (164, 168). The recurrence rate is 
high- er for patients with a previous amputation because of abnor- 
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mal distribution of plantar pressures and altered osseous 
architecture. The cumulative risks of neuropathy, deformity, high 
plantar pressure, poor glucose control, and male gen- der are all 
additive factors for pedal ulceration in these dia- betic patients (26, 
46, 50, 57, 111). Re-amputation can be attributed to disease 
progression, nonhealing wounds, and additional risk factors for 
limb loss that develop as a result of the first amputation.‖  
HISTORY 
―A thorough medical and foot history must be obtained from 
the patient. The history should address several  specific diabetic 
foot issues (Table 2).‖ 
PHYSICAL EXAMINATION 
―All patients with diabetes require a pedal  inspection 
whenever they present to any health care practitioner,  and they 
should receive a thorough lower extremity examina- tion at least 
once annually (175). Patients with complaints relating to the 
diabetic foot require more frequent detailed evaluations. The 
examination should be performed system- atically so that important 
aspects are not overlooked (62). It begins with a gross evaluation of 
the patient and extremi- ties. Any obvious problem can then receive 
closer scrutiny. Key components of the foot examination are 
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presented in Table 3. Although not specifically mentioned in this 
section,  it  is  assumed  that  a  general  medical     assessment 
(including vital sign measurements) will be obtained.‖ 
 
Diagnostic Procedures 
―Diagnostic procedures may be indicated in the assess- ment 
and care of the diabetic foot. Consideration should be given to the 
following tests in concert with those suggested by members of the 
consulting team. It should be noted that many of the following 





―Clinical laboratory tests that may be needed in  appropri- ate 
clinical situations include fasting or random blood glu- cose, 
glycohemoglobin (HbA1c), complete blood count (CBC) with or 
without differential, erythrocyte sedimenta- tion rate (ESR), serum 
chemistries, C-reactive protein, alka- line phosphatase, wound and 
blood cultures, and urinalysis. Caution must be exercised in the 
interpretation of laborato- ry tests in these patients, because several 
reports have doc- umented the absence of leukocytosis in the 
presence of severe foot infections (117, 122, 151, 176-178). A 
common sign of persistent infection is recalcitrant hyperglycemia 
despite usual antihyperglycemic regimens (150).‖ 
IMAGING STUDIES 
―The diabetic foot may be predisposed to both common and 
unusual infectious or noninfectious processes, partially because of 
the complex nature of diabetes and its associat- ed vascular and 
neuropathic complications. As a result, imaging presentations will 
vary due to lack of specificity in complex clinical circumstances 
(179-181). Such variability creates a challenge in the interpretation 
of imaging studies. Therefore, imaging studies should only be 
ordered to estab- lish or confirm a suspected diagnosis and/or direct 
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patient management. Distinguishing osteomyelitis from aseptic 
neuropathic arthropathy is not easy, and all imaging studies (Fig 4) 
must be interpreted in conjunction with the clinical findings (123, 
151).‖ 
―Plain radiographs should be the initial imaging study  in 
diabetic patients with signs and symptoms of a diabetic foot 
disorder (180, 182).‖ 
―Radiographs can detect osteomyelitis, osteolysis, fractures, 
dislocations seen in neuropathic arthropathy, medial arterial 
calcification, soft tissue gas, and foreign bodies as well as structural 
foot deformities, pres- ence of arthritis, and biomechanical 
alterations (183). Acute osteomyelitis might not demonstrate 
osseous changes for up to 14 days. Serial radiographs should be 
obtained in the face of an initial negative radiographic image and a 
high clinical suspicion of osseous disease (117, 123).‖ 
―Technetium-99 methylene diphosphonate (Tc-99 MDP) bone 
scans are often used in diabetic foot infection to deter- mine the 
presence of osteomyelitis. Although highly sensi- tive, this 
modality lacks specificity in the neuropathic foot (184, 185). 
Osteomyelitis, fractures, arthritis, and neuro- pathic arthropathy 
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will all demonstrate increased radiotrac- er uptake. However, a 
negative bone scan is strong evidence against the presence of 
infection. To improve the specifici- ty of nuclear imaging, white 
blood cells can be labeled with Tc-99 
hexamethylpropyleneamineoxime (Tc-99 HMPAO), indium-111 
oxime, or gallium-67 citrate (179, 186-189).‖ 
―Indium-111 selectively labels polymorphonuclear leuko- 
cytes and is more specific for acute infections than Tc-99 MDP 
scanning. Chronic infections and inflammation are not well imaged 
with indium-111, because chronic inflam- matory cells (ie, 
lymphocytes) predominate and are not well labeled with indium. 
Combining Tc-99 MDP and indium- 111 increases the specificity of 
diagnosing osteomyelitis (190). This combined technique is useful, 
because the Tc-99 MDP scan localizes the anatomic site of 
inflammation and the indium-111 labels the infected bone (180, 
191). The indium-111 scan is not typically positive in aseptic 
neuro- pathic arthropathy, although false-positive indium scans can 
occur (192-194). A 100% sensitivity and 89% specificity have been 
reported with the combined technique in evaluat- ing diabetic 




 VASCULAR EVALUATION 
―The lower extremity must be assessed for vascular and 
neuropathic risk factors. Although positive findings in  the 
neurologic examination rarely require further evaluation, positive 
findings of vascular insufficiency may require further consultation. 
The indications for vascular consultation include an ankle brachial 
index of less than 0.7, toe blood pressures less than 40 mmHg, or 
transcutaneous oxygen tension (TcPO2) levels less than 30 mmHg, 
since these measures of arterial perfusion are associated with 
impaired wound healing (27, 47, 87, 90, 212, 213).‖ 
―If the history and physical examination suggest  ischemia (ie, 
absent pedal pulses) or if a non healing ulcer is present, further 
evaluation in the form of noninvasive testing is  war- ranted.‖ 
―Noninvasive arterial studies should be performed  to 
determine lower extremity perfusion. Such studies may include 
Doppler segmental arterial pressures and waveform analysis, ankle-
brachial indices (ABI), toe blood pressures, and TcPO2 (89, 214, 
215). Ankle-brachial indices may be misleading, because ankle 
pressures can be falsely elevated 
 37 
due to medial arterial calcinosis and noncompressibility of 
affected arteries (52, 216, 217). A growing body evidence suggests 
that toe blood pressures in diabetic patients may have a role in 
predicting foot ulceration risk as well as predicting successful 
wound healing (213, 218, 219). TcPO2 measurements have received 
similar support in the literature (47, 87, 212). Although not 
consistently predictive of wound healing outcomes, these 
physiologic measures of tissue oxygenation are highly predictive of 
wound healing failure at levels below 25 mmHg (87, 212, 220). 
Both tests can be performed distally on the foot regardless of 
arterial calcification in the major pedal arteries, and they are  both 
favorable at pressures in the range of 40 mmHg (90, 212, 213).‖ 
―Laser Doppler velocimetry and measurement of skin  
perfusion pressure (SPP) have primarily been used in research 
settings, but can accurately assess blood flow and oxygen tension 
in the superficial arterioles and capillaries of the skin (220-225). 
Several recent reports indicate that laser Doppler measurement of 
SPP can be highly predictive of critical limb ischemia and wound 
healing failure at levels less than 30 mmHg (223, 224).‖ 
―Vascular consultation should be considered in the presence of 
abnormal noninvasive arterial studies or a nonheal- ing ulceration 
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(30, 54, 173, 215, 226). Arteriography with clearly visualized distal 
runoff allows appropriate assessment for potential revascularization 
(227-229). Magnetic resonance angiography (230) or CT angiogram 
are alternatives for evaluation of distal arterial perfusion (229, 
231).‖ 
NEUROLOGIC EVALUATION 
―Peripheral sensory neuropathy is the major risk factor  for 
diabetic foot ulceration (24, 26, 27, 46, 50). The patient  history and 
physical examination utilizing the 5.07 Semmes- Weinstein 
monofilament (10-g) wire are sufficient to identi- fy individuals at 
risk for ulceration (26, 232-235).‖ 
―Vibration perception threshold assessment with the  
biothesiometer is also useful in identifying patients at high risk for 
ulceration (44, 57, 236). More  sophisticated studies such as nerve 
conduction studies are rarely necessary to diagnose peripheral 
sensory neuropathy. Patients with neuropathic ulcerations usually 
have such profound sensory neuropathy that these studies add little 
to their clinical management (49).‖ 
PLANTAR FOOT PRESSURE ASSESSMENT 
―High plantar foot pressure is a significant risk factor  for 
ulceration (26, 45, 59, 70, 76, 80, 237). Measurement of high 
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plantar foot pressure is possible utilizing a variety of modalities. 
Several computerized systems can provide quantitative 
measurement of plantar foot pressure (76, 81, 238-241). While 
these measurements may be important in identifying areas of the 
foot at risk for ulceration and possibly in evaluating orthotic 
adjustments (57, 59), they are primarily used in diabetic foot 
research. The Harris mat, while not as sophisticated, can provide a 
qualitative measurement of plantar foot pressures and can identify 
potentially vulnerable areas for ulceration.(242).‖ 
EVALUATION OF ULCERS 
―The initial evaluation of the diabetic foot ulcer must  be 
comprehensive and systematic to ascertain the parameters that 
might have led to its onset as well as determine the presence of 
factors that can impair wound healing (25, 52, 54). Critical in this 
regard are assessments for vascular per- fusion (ischemia), 
infection/osteomyelitis, and neuropathy. As previously discussed, a 
thorough vascular evaluation must be performed; this includes 
palpation of pulses, clinical evaluation of capillary filling time, 
venous filling time, pallor on elevation, and dependent rubor (283). 
If pulses are not palpable or if clinical findings suggest ischemia,  
noninvasive arterial evaluation (eg, segmental Doppler pressures 
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with waveforms, ankle brachial indices, toe pressures, TcPO2 
measurements) and vascular surgical consultation are warranted. 
When required, these physiologic and anatomic data can be 
supplemented with the use of magnet- ic resonance angiography 
(230) or CT angiography (CTA) and subsequent use of 
arteriography with digital subtraction angiography (DSA) as 
necessary (77, 89, 284).‖ 
CLASSIFICATION OF DIABETIC ULCERS 
―Appropriate classification of the foot wound is based  on a 
thorough assessment. Classification should facilitate treat- ment and 
be generally predictive of expected outcomes. Several systems of 
ulcer classification are currently in use in the US and abroad to 
describe these lesions and commu- nicate severity (62, 90, 288-
292). Perhaps the easiest system is to classify lesions as 
neuropathic, ischemic, or neuro- ischemic, with descriptors of 
wound size, depth, and infec- tion (90). Regardless of which 
system is used, the clinician must be able to easily categorize the 
wound and, once clas- sified, the ensuing treatment should be 
directed by the underlying severity of pathology.‖ 
―Although no single system has been universally adopted, the 
classification system most often used was described and 
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popularized by Wagner (292). In the Wagner system foot lesions are 
divided into six grades based on the depth of the wound and 
extent of tissue necrosis 
the University of Texas San Antonio (UTSA) sys- tem  
associates lesion depth with both ischemia and infection (290). This 
system has been validated and is generally predictive of outcome, 
since increasing grade and stage of wounds are less likely to heal 
without revascular- ization or amputation (290, 293). The UTSA 
system is now widely used in many clinical trials and diabetic foot 
centers.‖ 
 
Figure  Assessment of a diabetic foot ulcer includes not 
only a description of the skin lesion but also the find- ings necessary 
for accu- rate assessment of the contributing factors and etiology. 
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Tissue Management / Wound Bed Preparation 
DEBRIDEMENT.  
“Debridement of necrotic tissue is an inte- gral component in 
the treatment of chronic wounds since they will not heal in the 
presence of unviable tissue, debris, or critical colonization (314, 
315). Undermined tissue or closed wound spaces will otherwise 
harbor bacterial growth (312, 316, 317). Debridement serves 
various functions: removal of necrotic tissue and callus; reduction 
of pressure; evaluation of the wound bed; evaluation of tracking 
and tunneling; and reduction of bacterial burden (318,  319). 
Debridement facilitates drainage and stimulates healing (320). 
However, debridement may be contraindicated in arterial ulcers 
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(321). Additionally, except in avascular cases, adequate debridement 
must always precede the application of topical wound healing 
agents, dressings, or wound clo- sure procedures (30, 288, 322, 
323). Of the five types of debridement (surgical, enzymatic, 
autolytic, mechanical, biological), only surgical debridement has 
been proven to be efficacious in clinical trials (323).‖ 
Surgical debridement. “Surgical debridement is the cor- 
nerstone of management of diabetic foot ulcers. Thorough sharp 
debridement of all nonviable soft tissue and bone from the open 
wound is accomplished primarily with a scalpel, tissue nippers, 
curettes, and curved scissors (324). Excision of necrotic tissue 
extends as deeply and proximally as necessary until healthy, 
bleeding soft tissue and bone are encountered. Any callus tissue 
surrounding the ulcer must also be removed. The main purpose of 
surgical debridement is to turn a chronic ulcer into an acute, 
healing wound (325). A diabetic ulcer associated with a deep 
abscess requires hospital admission and immediate incision and 
drainage (178). Joint resection or partial amputation of the foot is 
necessary if osteomyelitis, joint infection, or gan- grene are present 
(41, 100, 123, 151, 180, 271).When surgical or sharp debridement 
is not indicated, other types of debridement can be used. For 
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example, vas- cular wounds may benefit from enzymatic 
debridement, while an extremely painful wound may benefit from 
autolytic debridement. Mechanical debridement is  often used to 
cleanse wounds prior to surgical or sharp debride- ment. In areas 
where the medical staff is not trained in sur- gical or sharp 






Figure  “New technologies have been developed that have 
proved useful  for management of diabetic ulcerations. (A)Platelet-
rich plasma (PRP) involves use of the patient’s blood, which is 
collected and then fractionated through centrifuga- tion. A platelet-
rich and platelet-poor supernatant remains. (B) This case involved 
use of autologous platelet-rich plasma gel activated with thrombin 
and placed onto a healthy wound bed. (C) The platelet gel or clot 
may also be covered with a synthetic skin graft  substitute.‖ 
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METHODOLOGY AND MATERIALS 
This study was conducted in the Institute of General Surgery, 
RGGGH. The Institute receives large number of diabetic foot 
patients. In that 50 patients were included in the study between July 
2015 to September 2015. Patients with Chronic Diabetic Foot and 
previous amputations were also included in the study. Patients were 
recruited from the surgical OPD and admitted. Data were collected 
by detailed history, clinical examination, wound or ulcer and were 
recorded in the pre-designed profoma. Age, sex, socioeconomic 
status, duration and type of diabetes, wagner’s classification, 
examination findings, blood investigations, renal function test, 
swab of  the wound. X-ray and treatment provided were collected. 
Treatment was carried out in both medical and surgical means. 
Antibiotics – aminoglycosides, cephalosporins, penicillin 
derivatives were used. 
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RESULTS 
 Table-1: Sociodemographic characteristics of the patients  
Characteristics Number %age 
Age/years   
<40 4 8 
41-50 24 48 
51-60 16 32 




Sex Number % 
Male 31 62 
Female 19 38 
 
Characteristics Number % 
Type of diabetes 
Type I  1 2 
Type II  49 98 
Socioeconomic status 
Lower 7 14 
Middle 30 60 
Upper 13 26 
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Table 2- Number of patients according to Wagner’s classification 
(n=50)  
Grade No.of Patients % 
0 3 6 
1 7 14 
2 12 24 
3 15 30 
4 11 22 
5 2 4 
Distribution according to Wagner’s Classification  
 
 51 
Table 3- Treatment provided 
Type of Treatment No. of Patients % 
Antibiotics alone 8 16 
Incision and drainage 2 4 
Debridement 14 28 
Amputation 25 50 





Type of amputation No.of patient 
Rye’s/toe 16 
Syme’s 4 




Table 4– Cause of Mortality in Diabetic foot disease (n=3) 
Cause Number of patients 
Septicaemia 2 
Ketoacidosis 1 
Chronic renal failure 1 
Table 5- Culture report 
Investigations No.of patients % 
Culture   
Staph.aureus Isolated 13 26 
Mixed 25 50 
From the above observed data , most of the patients presented 
with advanced grade, grade 2 – 24%, grade 3-30%, grade 4 – 22%. 
Henceforth surgical management was required in most of the 
patients. Amputation in half of the Ptients and debridement in 28% 
of patients highlighting the advanced disease at presentation.  
Wagner’s classification may be different for a surgeon as 
compared to physician because patients come to a surgeon with 
advanced disease hence the greater grade of patients were in our 
study in more percentage. 
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DISCUSSION  
Diabetes is associated with complications in its long run. Foot 
infection and subsequent amputation of a lower extremity are one 
of the most common reason for hospitalisation. As observed in our 
study, it is more common in males. More common age group is 
between 40-60 in our study. The hallmark of diabetic foot is its 
gross infection and major contributing factors for late presentation 
are poor knowledge about the disease, undetected diabetes, trust in 
faith healers, bare foot gait.  
Peripheral neuropathy and infection are common risk factors 
diabetic foot. In our study mixred infection, includes aerobes, 
anaerobes, is common 
The standard treatment for diabetic foot according to 
Wagner’s classification is  
1. Grade 0 - Prevention 
2. Grade 1 -  Antibiotics and good glycemic control 
3. Grade 2 – hospitalisation as they need surgical 
management alonmg with antibiotics and glycemic control  
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4. Grade 3 – requires some sort of amputation 
5. Grade 4 – wide debridement along with amputation 
6. Grade 5 – preferred treatment is below knee amputation 
There were 4 mortalities in our study, al had high Wagner’s 
score.of these 2 was due to septicemia, 1 due to ketoacidosis, 1 due 
to chronic renal failure. 
Prevention strategy including patient education in foot care, 
prophylactic skin and nail care and foot wear reduces the risk of 
foot ulceration and amputation rates. 
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CONCLUSION 
Diabetic foot and its complications are troublesome, source 
consuming and producing disability, morbidity and mortality.  
PREVENTION IS THE BEST TREATMENT 
Grading of the diabetec foot lesions according to Wagner’s 
classification helps in choosing appropriate treatment to the grade.  
Patient education and strict glycemic control can reduce the burden 
of diabetic foot. Early diagnosis and hospitalization, appropriate 
treatment including medical and surgical treatment according to the 
grade can reduce the morbidity mortality and improve the outcome 
of the disease 
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PATIENT CONSENT FORM 
STUDY TITLE:  ―EVALUATION AND MANAGEMENT OF 
DIABETIC FOOT ACCORDING TO WAGNER’S 
CLASSIFICATION‖ 
STUDY CENTRE 
Rajiv Gandhi Government General hospital and Madras Medical College.  
PARTICIPANT NAME:    AGE:  SEX: 
I.P. NO : 
I confirm that I have understood the purpose of treatment and procedure for 
the above study. I have the opportunity to ask the question and all my 
questions and doubts have been answered to my satisfaction.  
I have been explained about the possible complications that may occur during 
the interventional  procedure. I understand that my participation in the study 
is voluntary and that I am free to withdraw at any time without giving any 
reason. 
I understand that the investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study.  
I hereby consent to participate in this study of the ―EVALUATION AND 
MANAGEMENT OF DIABETIC FOOT ACCORDING TO WAGNER’S 
CLASSIFICATION‖ 
 
Date:    signature / thumb impression of patient  
Place:      
Patient’s name: 
Signature of the Investigator:  ______________________ 




We are conducting a study on “EVALUATION AND 
MANAGEMENT OF DIABETIC FOOT ACCORDING TO 
WAGNER’S CLASSIFICATION” among patients attending Rajiv 
Gandhi Government General Hospital, Chennai and for that your 
information is valuable to us. 
The purpose of this study is to assess the magnitude of 
problem and  evaluate and manage the different lesions of diabetic 
foot according to Wagner classification at RGGGH,Chennai. 
 
We are selecting certain cases and if you are found eligible, 
we may be using your information which in any way do not affect 
your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are 
otherwise entitled. 
The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal 




Signature of the Participant  




DATA COLLECTION SHEET 
I. Patient particulars:   
Name                                   DOA                          Case No. 
Age                                      DOS                       I.p.No. 









HISTORY OF PREVIOUS OPERATION - 
DURATION OF DIABETES  - 
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Operated /Non operated- 
     
 
POST OPERATIVE COURSE: 
      Recovery -  






KEY TO MASTER CHART  
Sex – M-Male; F-female 
Type - type of diabetes – I;II 
Culture- Mx-mixed organisms; S- stap.aureus alone 
―Wagner’s Classification for diabetic foot disease (adopted from Levin 
and O’Neals)‖- 
Grade Description 
Grade 0 High risk foot and no ulceration 
Grade 1 Superficial Ulcer; Total destruction of the 
thickness of the skin  
Grade 2 Deep Ulcer (cellulitis); Penetrates through 
skin,fat,ligaments not affecting bone 
Grade 3 Osteomyelitis with Ulceration or abscess 
Grade 4 Gangrenous patches limited to toes or part of the 
foot 
Grade 5 Gangrene of the entire foot  
Treatment- A-antibiotics;Amp-amputation (of any type);D-
debridment;I&D- incision and drainage 
Rft- renal function test ; Ab-abnormal; N-normal 
Mortality- yes;no  Cause- Sep-Sepsis; DKA-Diabetic 
Ketoacidosis; CRF- Chronic Renal Failure 
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MASTER CHART 
S.No Name Age Sex Type Culture Wagner’s Treatment Rft Mortality/Cause 
1 Elumalai 50 M II Mx 3 D N No 
2 Murugan 52 M II  1 A N No 
3 Murugesan 47 M II S 2 D N No 
4 Marimuthu 65 M II Mx 4 Amp Ab Yes/Sep 
5 Natesan 43 M II  2 D N No 
6 Nagendran 44 M II  1 I&D N No 
7 Natarajan 46 M II Mx 3 Amp Ab No 
8 Muthu 42 M II Mx 3 Amp N No 
9 Rajesh 37 M II Mx 4 Amp N No 
10 Raju 36 M I  0 A N No 
11 Ravi 54 M II Mx 3 Amp N No 
12 Mahesh 52 M II S 3 Amp N No 
13 Mani 51 M II Mx 3 Amp N No 
14 Manikandan 47 M II S 2 D N No 
15 George 68 M II Mx 3 D Ab Yes/CRF 
16 Christian 47 M II Mx 2 D N No 
17 Nagesh 56 M II S 1 I&D Ab No 
18 Karthik 39 M II  0 A N No 
19 Balaji 57 M II Mx 3 Amp Ab No 
20 Balamurugan 59 M II Mx 4 Amp Ab No 
21 Subramani 58 M II S 4 Amp N No 
22 Silambarasan 47 M II  1 Ssg N No 
23 Arasu 46 M II Mx 3 Amp N No 
24 Arapuli 65 M II S 2 D N No 
25 Kangeyan 61 M II Mx 5 Amp Ab Yes/Sep 
26 Dharmalingam 48 M II Mx 3 Amp N No 
27 Kesavan 56 M II Mx 4 Amp N No 
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S.No Name Age Sex Type Culture Wagner’s Treatment Rft Mortality/Cause 
28 Gajendran 49 M II  0 A N NO 
29 Iqbal 52 M II S 2 D N No 
30 Ismail 47 M II Mx 4 Amp N No 
31 Mohammed 57 M II Mx 3 Amp N No 
32 Rajeshwari 58 F II S 2 D N No 
33 Lakshmi 46 F II Mx 3 Amp Ab No 
34 Mahalaksmi 47 F II S 2 D N No 
35 Muniyammal 48 F II Mx 4 Amp Ab No 
36 Ellamal 49 F II S 2 D N No 
37 Muthulakshmi 39 F II  1 A N No 
38 Pothumpon 48 F II Mx 4 Amp N No 
39 Shakthi 49 F II S 3 Amp N No 
40 Mani 47 F II  1 A N No 
41 Maheshwari 46 F II Mx 4 Amp N No 
42 Eshwari 47 F II Mx 4 Amp N No 
43 Sulthana 53 F II Mx 3 Amp N No 
44 Indira 56 F II  2 D N No 
45 Raji 54 F II  2 A N No 
46 Anjalai 55 F II Mx 4 Amp N No 
47 Nageshwari 47 F II S 2 D N No 
48 Patchaiyammal 70 F II Mx 5 Amp Ab Yes/DKA 
49 Murugeshwari 47 F II  1 A N No 
50 Rekha 50 F II S 3 D N No 
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